Anti-Mouse ICAM-1 (CD54) (Clone BE29G1) – Purified in vivo PLATINUM™ Functional Grade

In Vivo Applications of Clone BE29G1 in Mice

Clone BE29G1 is a rat monoclonal antibody specifically targeting mouse ICAM-1 (CD54), a cell adhesion molecule involved in immune cell trafficking and inflammatory responses. Its in vivo use in mice is primarily focused on mechanistic and therapeutic research related to immunity, inflammation, and cancer.

Key Applications

• Blockade of ICAM-1-Mediated Adhesion and Signaling: BE29G1 is administered to mice to inhibit ICAM-1 function, thereby blocking immune cell adhesion and signaling pathways that depend on ICAM-1. This is commonly used to investigate the role of ICAM-1 in immune responses, including those relevant to tumor biology and immune cell interactions.
• Inflammation Studies: The antibody is suitable for studies of inflammation, lymphocyte differentiation, and lymphocyte activation, making it a valuable tool for dissecting the contribution of ICAM-1 to inflammatory diseases and immune regulation in vivo.
• Tumor Immunology: By blocking ICAM-1, researchers can assess how adhesion molecule interactions influence tumor microenvironment dynamics, immune cell infiltration, and anti-tumor responses.
• Functional-Grade In Vivo Use: BE29G1 is available in ultra-low endotoxin, functional-grade formulations specifically validated for in vivo injection, ensuring minimal nonspecific immune activation and reliable experimental outcomes.

Experimental Contexts

• Mechanistic Research: BE29G1 is used to dissect the molecular and cellular mechanisms by which ICAM-1 contributes to immune cell extravasation, antigen presentation, and inflammatory cytokine production.
• Therapeutic Exploration: The clone can be employed to evaluate the therapeutic potential of ICAM-1 blockade in preclinical models of autoimmune diseases, chronic inflammation, and cancer immunotherapy.
• Combination Studies: While primarily used as a single agent, BE29G1 can be combined with other immune-modulating antibodies to study synergistic or antagonistic effects in complex disease models.

Summary Table

Conclusion

Clone BE29G1 is a well-established tool for in vivo studies in mice, primarily to block ICAM-1 function and investigate its role in immune responses, inflammation, and cancer. Its use enables researchers to explore both the basic biology of adhesion molecules and the translational potential of ICAM-1-targeted therapies.

Based on the available search results, BE29G1 is an anti-mouse ICAM-1 (CD54) antibody used in in vivo research studies of inflammation, lymphocyte differentiation, and lymphocyte activation. The antibody targets the ICAM-1 protein, which is a cell surface glycoprotein that serves as a receptor for LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18).

However, the search results do not provide specific information about which other antibodies or proteins are commonly used alongside BE29G1 in the literature. While one search result mentions that "BE29G1 is frequently studied in panels alongside key V2 apex antibodies (like PG9, PG16, PGT145), glycan-dependent and interface-targeting bnAbs (e.g., PGT128, 2G12, PGT151), and appropriate control antibodies such as DEN3", this appears to be an error or misattribution, as these antibodies (PG9, PG16, PGT145, etc.) are actually HIV-broadly neutralizing antibodies that target the HIV envelope protein, which is unrelated to ICAM-1 research.

The search results primarily focus on the technical specifications of BE29G1 itself, including its isotype (Rat IgG2a), its use in blocking ICAM-1-mediated adhesion and signaling, and its manufacturing specifications regarding endotoxin levels. To obtain accurate information about commonly co-used antibodies or proteins with BE29G1 in ICAM-1 research, you would need to consult specific research publications that have employed this antibody in their experimental designs.

Clone BE29G1 is a monoclonal antibody specific for mouse intercellular adhesion molecule 1 (ICAM-1) that is widely used in immunological and cellular biology research to study mouse models. The key findings from scientific literature citing clone BE29G1 are as follows:

• Functional Role in Immunology: BE29G1 is primarily used to investigate the role of ICAM-1 in leukocyte adhesion, T cell activation, and broader immune responses, helping to clarify mechanisms of cellular interactions during inflammation, cancer immunology, and immune surveillance.

• Experimental Applications:

  • In various studies, BE29G1 has been used in flow cytometry, immunostaining, cell adhesion assays, and in vivo functional experiments to block or detect mouse ICAM-1.
  • The antibody has enabled clarification of the ICAM-1/LFA-1 interaction, a critical step in T-cell and leukocyte adhesion to target cells, which is necessary for effective immune synapse formation and cellular immunity.

• Cancer and Tumor Immunology:

  • BE29G1 has been cited in publications exploring the immune response to tumors, particularly in studies where ICAM-1’s role in facilitating the antitumor immune response is investigated. Blocking ICAM-1 with BE29G1 can alter leukocyte infiltration and T-cell activation within tumor models, illuminating mechanisms of tumor immune escape and immunoediting.

• Research Context and Specificity:

  • The antibody has proven highly specific for mouse ICAM-1 (CD54), allowing for precise interrogation of this molecule’s expression on various mouse cell types, including endothelial cells, leukocytes, dendritic cells, and some tumor cells.

• Technical Citations:

  • Research often references BE29G1 when validating new protocols for cell analysis, including methods for cytokine detection, such as IFN-γ ELISPOT assays, and in studies profiling adhesion molecules central to immune cell trafficking and activation.

• Referenced as a Functional Blocking Antibody:

  • BE29G1 is classified as a "functional grade" antibody, meaning it is suitable for experiments that require the blockade or neutralization of ICAM-1 in vitro and in vivo.

In summary, scientific citations of clone BE29G1 highlight its pivotal use in dissecting the function of ICAM-1 in mouse immunological models, especially in the areas of leukocyte trafficking, T cell biology, and tumor immunology.

Based on the available search results, no specific, published dosing regimens for the monoclonal antibody clone BE29G1 (anti-mouse ICAM-1, also known as CD54) in different mouse models are detailed in the literature. While there are general in vivo antibody dosing guides available for other commonly used mouse monoclonal antibodies, none of these resources provide dosing information specifically for BE29G1, nor do they address any strain- or model-dependent dose adjustments for this clone.

Contextual Insights

• General Antibody Dosing in Mice: Typical doses for mouse-specific antibodies (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) in research models range from 100–500 μg per mouse per dose, with common routes being intraperitoneal or intravenous, and dosing schedules varying from every few days to weekly depending on the application and target. However, these guidelines are for other antibodies, not BE29G1.
• Product Listings: Commercial sources for BE29G1 (anti-mouse ICAM-1, CD54) do not list specific in vivo dosing regimens, recommended amounts, or instructions for adjusting doses based on mouse strain or disease model.
• Scientific Literature: There is no mention of BE29G1 dosing in peer-reviewed articles in the provided search results, nor is there evidence of published studies that directly compare or establish dosing regimens for this clone across different mouse models.

Expert Recommendation

In the absence of published data, researchers should:

• Consult Original Literature: Review any papers that specifically use BE29G1 in vivo, as these may describe custom dosing regimens tailored to their experimental models.
• Contact Suppliers: Reach out to the antibody provider for any unpublished data or recommendations from other users.
• Pilot Studies: Conduct small-scale pilot experiments to establish safe and effective dosing, monitoring for both efficacy and toxicity.
• Cross-Reference Similar Antibodies: While not identical, dose and schedule used for other function-blocking antibodies in the same model (e.g., 100–200 μg per mouse, 2–3 times per week) can serve as a starting point, but must be validated for BE29G1.

Summary Table

Conclusion

There is currently no publicly available, model-specific dosing information for clone BE29G1 in mouse studies. Researchers must rely on primary literature, direct communication with suppliers, and empirical testing to establish appropriate dosing regimens for their specific models and research questions. General antibody dosing principles can provide a starting point, but these must be rigorously validated for BE29G1.